創新奇智2021年營收增長86.3%,“AI+製造”業務大增1.3倍
格隆匯3月30日丨創新奇智(2121.HK)發佈截至2021年12月31日止年度業績,期內營業收入8.61億人民幣,同比增長86.3%,其中,“AI+製造”業務增長強勁,全年收入4.49億元,同比增長132.5%,成為公司第一大業務板塊。集團毛利率31%,較上年提升1.9個百分點。經調整淨利潤為虧損141.8百萬元,調整後淨虧損率16.5%,同比縮窄47.3%。
研發費用3.28億人民幣,研發投入同比增8成。優質客户數目增長82.6%,復購率102.5%。累計申請634項AI相關專利,90%以上發明專利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.